cancer after liver transplantation (lt) constitutes a threat also for young recipients, but cancer risk factors are usually absent in children and large studies on the cancer risk profile in young lt recipients are scarce. Data of patients younger than 30 years who underwent lt during the period 1982-2013 in the nordic countries were linked with respective national cancer registries to calculate standardized incidence ratios (Sirs). a total of 37 cancer cases were observed in 923 patients with 7846 person-years of follow-up. the Sir for all cancer types, compared with the matched general population, was 9.8 (12.4 for males and 7.8 for females). cumulative incidence of cancer adjusted for the competing risk of death was 2% at 10 years, 6% at 20 years, and 22% at 25 years after lt. non-Hodgkin lymphoma was the most common cancer type (n = 14) followed by colorectal (n = 4) and hepatocellular cancer (n = 4). age was a significant risk factor for cancer, and the absolute risk of most cancers (except for lymphoma) increased considerably in young adults older than 20 years. the cancer risk pattern is different in pediatric and young lt patients compared with adult recipients. the striking increase in cancer incidence in young adulthood after the second decade of life deserves further consideration in transition programs.
specifically in pediatric and young adult patients. In studies involving both adults and children, (1, 3) risk factors specific to children and young adults are usually not reported. Most studies of pediatric populations have focused on posttransplant lymphoproliferative disease, (5) (6) (7) but few have assessed other types of cancer. The largest studies on this topic included all types of solid organ transplant patients (7) (8) (9) or only kidney transplant patients, (10) but there are no large studies on young Liver Transplant patients.
In this Nordic multicenter study, we analyzed the incidence and types of post-LT cancer among patients transplanted before 30 years of age and compared the cancer risk with the matched general population.
Patients and Methods
Patient data were derived from the Nordic Liver Transplant Registry, which includes records of all LT patients in Finland, Sweden, Norway, and Denmark since 1982. Nordic Liver Transplant Registry data are maintained by the Nordic Liver Transplant Group and stored at Scandiatransplant in Aarhus University Hospital, Denmark. Scandiatransplant is the official organ exchange organization in the Nordic countries. The study protocol received a priori approval by the appropriate institutional review boards in each country.
The study included all patients who underwent LT at ages 0-30 years between 1982 and 2013. The data included date of birth, sex, date of LT and re-LT, indication for LT, country of LT, and immunosuppressive medication used during the first month after LT.
Cancer diagnosis was identified via the national cancer registry in each country and linked to our study patients using the unique personal identity number. Follow-up for cancer started at the date of the first LT and ended at death, emigration, or study closure on December 31, 2013. Neoplasms are recorded according to the 3rd edition of the International Classification of Diseases for Oncology. Regarding hematologic neoplasms, only definite malignant cases were considered, excluding nondestructive (early lesion) lymphoproliferative disorders.
The cancer registration system in the Nordic countries is virtually complete, (11) and the computerized record linkage procedure is precise, (12) thus providing unbiased control data and accurate comparisons for the study. Basal cell carcinoma was not included in the nonmelanoma skin cancer category.
STATISTICAL ANALYSIS
The numbers of cancer cases and person-years at risk were counted by 5-year age groups, separately for each calendar year and country. The expected number of cases of all cancers combined and of specific cancer types were calculated by multiplying the number of person-years in each sex and age group by the corresponding cancer incidence rate in each country during the period of observation. The standardized incidence ratio (SIR) was calculated by dividing the observed number of cases by the expected number of cases. The 95% confidence intervals (CIs) for the SIR were based on the assumption that the number of observed cases followed a Poisson distribution. (13) Hepatocellular cancer diagnosis recorded in cancer registries within 6 months after LT was considered as pre-LT cancer that had been confirmed with a delay (n = 7), and it was thus excluded from the de novo post-LT cancer count. Cumulative incidence was calculated with the competing risk method according to Fine and Gray (14) with mortality held as a competing risk. Age-adjusted hazard ratios by Cox regression analyses were calculated for sex, country and era of LT, indication, and type of immunosuppression. Any type of post-LT cancer was considered as the outcome variable. Non-Hodgkin lymphoma was also analyzed separately. P values < 0.05 were considered statistically significant.
results
The study comprised 923 patients with 7846 person-years of follow-up. Of these patients, 464 (50%) were male, and 544 (59%) had undergone LT after the year 2000 (Table 1 ). The most common LT indication was biliary atresia (26%; Table 1 ). Information on immunosuppressive medication was available for 652 (71%) patients in the Nordic Liver Transplant registry.
During the study follow-up, we observed 37 de novo cancer cases. Non-Hodgkin lymphoma was the most common cancer type (n = 14). The distribution of cancer types is shown in Fig. 1 of de novo cancer after adjustment for the competing risk of death was 2% at 10 years, 6% at 20 years, and 22% at 25 years after LT in patients at risk (Fig. 2) .
Of all cancers, 8 (22%) occurred within 2 years after LT; 14 (38%) occurred at 2-9 years; and 15 (41%) occurred beyond 10 years after LT (Fig. 3) . The occurrence of cancer in relationship to age and time after LT is shown in Fig. 4 . Cancer types other than lymphomas were very rare in patients younger than 20 years (Fig. 4) .
Of non-Hodgkin lymphomas, 11 (79%) occurred in male patients. A total of 10 cases (71%) were observed in patients younger than 30 years. All 3 kidney cancers occurred in females older than 30 years at cancer diagnosis. Both cases of nonmelanoma skin cancer occurred in males and after 10 years after LT (both at a age > 30 years). Only 1 of 4 colorectal cancers was diagnosed at a younger age than 30 years and at < 10 years after LT. Three of 4 colorectal cancers occurred in patients transplanted for primary sclerosing cholangitis. All de novo liver cancers occurred more than 4 years after LT (mean, 6.7 years) at a mean age of 24 years with 3 of 4 liver cancers occurring in males.
STANDARDIZED INCIDENCE RATIo
The overall SIR for all cancer types was 9.8 (95% CI, 6.8-13.3): for males it was 12.4 (95% CI, 7.5-19.4) and for females it was 7.8 (95% CI, 4.6-12.3), respectively. SIRs for cancer types with at least 2 observed cases are shown in Table 2 . SIRs and cancer incidence rates according to age group are shown in Table 3 .
RISK FACToR ANALYSIS
By Cox regression analysis, increasing age and antimetabolite use were the only factors significantly associated with increased posttransplant overall cancer risk (Table 4) . When non-Hodgkin lymphoma was considered, male sex was the only significant age-adjusted risk factor (hazard ratio, 5.2; 95% CI, 1.2-23.4; P = 0.03).
Discussion
Although post-LT cancer rates proved to be 10-fold higher in young LT recipients compared with the general population, absolute cancer risk was very low with approximately 3-7 cases per 100 patients during a 10-year follow-up. The cumulative incidence of cancer was only 2% at 10 years after LT but increased considerably during the second decade, reaching 22% at 25 years after LT for patients at risk. Non-Hodgkin lymphoma was the most common cancer type across all ages and all follow-up periods, followed by hepatocellular, colorectal, and kidney cancer. Overall, we found that post-LT cancer, other than lymphoma, becomes a much more relevant issue in young adults (older than 20 years) compared with children, regardless of time elapsed after LT.
Our findings have direct clinical implications. First, the sharp increase in cancer risk after the second decade of life is in practice after transition to adult care. This issue merits further consideration in transition programs and in the further follow-up of young LT patients. Second, clinicians should evaluate exposure to known cancer risk Original article | 1255
factors, such as alcohol use, smoking, and obesity, and be vigilant for any new symptoms potentially attributed to cancer. Third, the immunosuppression regimen deserves also to be reviewed on a regular basis. Previous studies have reported cancer incidences of 0.3-1.1 per 100 person-years of follow-up in pediatric kidney transplant recipients, (8, 10) and 0.9 per 100 person-years of follow-up in pediatric LT recipients. (8) Our cancer incidence of 0.3-0.7 per 100 person-years, depending on age, is within the range reported by others. Francis et al. reported a cumulative incidence of all cancers of 27% at 25 years after first kidney transplantation, (10) which is also fairly close to the cumulative incidence in our study.
Previously reported SIRs for all cancer types vary from 12.5 to 19.1, (7, 8) and the SIR for nonskin cancers was 8.2 in 1 study. (10) The largest study involving all types of pediatric solid organ transplant recipients found elevated SIRs for non-Hodgkin lymphoma, Hodgkin lymphoma, leukemia, myeloma, and cancers of the kidney, thyroid, liver, testis, soft tissue, ovary, bladder, and vulva. (7) Non-Hodgkin lymphoma was the most common cancer type in all of these studies, accounting for 30%-80% of all cancer cases (7) (8) (9) 15) and with SIRs ranging from 46 to 212. (7, 8, 10) These studies differ from our study by including either all types of organ transplants or only kidney transplants, including only patients transplanted at ages 0-18 and in the age structure of patients and length of follow-up. (7) (8) (9) (10) 15) Although LT patients were included in some studies, (7) (8) (9) it is difficult to draw conclusions on the cancer risk pattern specifically for young LT patients because analyses were mostly performed in groups combining all types of solid organ transplants. Cancer SIR is heavily influenced by the age structure of 
FIG. 1. Number of cases observed for various cancer types after LT.
the patient cohort and length of follow-up. SIRs generally decrease with age although absolute excess risk may rise because cancer incidence in the background population also rises with age. The somewhat lower cancer SIRs observed in our study are therefore possibly explained by our inclusion of young adults (aged 18-30 at LT). Young adults may differ from pediatric patients as well as middle-aged and older adults in the length of environmental exposures (eg, alcohol and smoking), comorbidity, and with regards to LT indication. No specific cancer surveillance guidelines exist for young adult LT patients. Figure 5 shows a comparison of the spectrum of cancer risk between the present pediatric cohort and the corresponding Nordic adult LT cohort as previously reported. (2) In adults, significantly elevated SIRs were observed for oropharyngeal cancers, biliary, pancreatic and lung cancer, whereas no such cases were observed in the present study cohort (Fig. 5) .
Despite elevated cancer SIRs in young LT recipients, a recent Nordic study found no increased mortality from cancer among 1-year surviving pediatric LT patients compared with the matched general population. (16) This may be due to a successful cancer treatment in most of these cases. However, the relatively low number of cancer cases and limited follow-up after cancer diagnosis or treatment restricts firm conclusions.
It is difficult to predict which young LT patient will develop cancer since no risk factor was strongly associated with cancer. Older age increased the risk for any cancer, which was also shown in a recent study. (10) A higher lymphoma risk was observed in male patients. The relatively small number of cases precluded risk factor analyses for other specific types of cancer.
The reason for an increased cancer risk with antimetabolite use (mycophenolate or azathioprine) was unclear, and multivariate analyses were not possible due to the limited number of cases. The risk estimates were also increased for non-Hodgkin lymphoma, but nonsignificant. Antimetabolites may affect viral replication, and mycophenolate has been associated with posttransplant cytomegalovirus disease. (17, 18) Viral disease is implicated in the pathophysiology of many pediatric posttransplant cancers, thus providing Original article | 1257 a possible mechanism for the association seen in our study between antimetabolite use and cancer. In adult transplant cohorts, the effect of mycophenolate on cancer risk is controversial. (19, 20) However, data on immunosuppression were available only from the first post-LT month and only for 71% of patients. We were unable to analyze whether antimetabolites were used in the long term and whether antimetabolite use was associated with different calcineurin inhibitor exposure in patients compared with those without antimetabolite use. Cancer incidence could thus not be weighed on cumulative load of immunosuppression, and our findings must be interpreted with severe caution.
We also observed an elevated SIR for colorectal cancer. This finding could be related to the inclusion of a relatively large proportion of patients with primary sclerosing cholangitis (11%), many of whom have concomitant inflammatory bowel disease. The majority (75%) of colorectal cancers occurred in patients with primary sclerosing cholangitis older than 30 years of age and several years after LT. Frequent colonoscopy surveillance is recommended for such patients.
In adult transplant recipients, skin cancer is the most common posttransplant cancer type. (1, 2) However, we observed only 2 cases of nonmelanoma skin cancer and no case of melanoma. Thus, skin cancer is extremely rare in pediatric LT patients, but similar to previous reports (8, 10, 21, 22) it becomes a relevant risk in young adulthood (>25-30 years of age).
The strengths of this study include the long follow-up (up to 31 years), the large sample of LT
FIG. 5.
A comparison of the spectrum of cancer risk, expressed as SIRs (with 95% CI), between the present pediatric LT cohort and Nordic adult LT patients from Nordin et al. (2) Cancer types (not observed in the pediatric cohort) with significantly elevated SIRs in the adult population are also shown. recipients, and the completeness of the cancer data within the Nordic Liver Transplant registry and the national cancer registries, as well as the unique ability to combine data from several countries. All Nordic LT patients under 30 years of age were included, without any exclusions, and each patient could be successfully linked with cancer registry data. The NORDCAN classification system, adapted for cancer data from all Nordic countries, allows for straightforward combination of data across countries. (23) A limitation of the study is the small number of cancer events that prevents conclusive analysis of individual cancers. Several risk factors for cancer could not be adjusted for in the present analyses, such as presence of inflammatory bowel disease (risk factor for colorectal cancer), viral status (Epstein-Barr virus and lymphoma risk), and environmental risk factors (eg, alcohol use, obesity, and smoking). Moreover, the registry data did not include information on the longterm type and doses of immunosuppression.
In conclusion, a unique cancer risk pattern exists among pediatric and young LT recipients. NonHodgkin lymphoma is the most common cancer type in these patients. The risk of other cancers increases considerably in young adulthood, after the second decade of life, compared with childhood, and this merits consideration in transition programs. This also calls for strategies to reduce cancer risk, and such strategies may include cancer surveillance recommendations specific to young adult transplant recipients. Larger studies are required to better clarify risk factors for specific cancer types in young transplant recipients. This can likely be achieved only by combining transplant cohorts from several countries. 
